India Pharma Outlook Team | Wednesday, 30 July 2025
Roche announced today new clinical data on trontinemab, its investigational Alzheimer drug that is intended to target amyloid plaques on an unprecedented scale of precision, to be presented today at the Alzheimer Association International Conference (AAIC) in Toronto.
The treatment, based on the Brainshuttle TM technology of Roche, demonstrated high potential of redefining the treatment of the early and even preclinical phases of the disease.
During the recent Phase Ib/IIa Brainshuttle AD trial, trontinemab was administered and was found to result in a profound and fast amyloid-reduction in patients with early symptomatic Alzheimer disease. With a dose of 3.6 mg/kg, 91 percent of individuals fell below the amyloid positivity threshold before 28 weeks, with 72 percent achieving deep clearance.
Also Read: Anti-Infectives: How New Research is Shaping Infection Control
Supported by a positive safety record and a low rate of ARIA-E, these data provide a preface to upcoming Phase III TRONTIER 1 and 2 studies to be initiated later this year by Roche.
Roche also declared a new Phase III study in preclinical Alzheimer and hopes that the drug will help conquer the disease by pharmacologically targeting people prior to the onset of symptoms and prevent disease progression.
In addition to its drug breakthroughs, Roche also showed results of an ultra-sensitive blood test, its Elecsys pTau217 that can detect the presence of Alzheimer disease in patients with the same accuracy as a PET scan, but only needs a routine blood sample draw.
It will also be fed into the screening of trials and is anticipated to bring breakthroughs to the realm of early detection into regular clinical practice. Alongside the combination of trontinemab and Elecsys diagnostics, Roche will push a strong agenda that narrows the gap in Alzheimer diagnosis, and provides timely intervention.
